Derazantinib
Phase 2Small molecule
Basilea PharmaceuticaDerazantinib is one of 2 small molecule programs targeting FGFR2 Fusions. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in FGFR2 Fusions
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Intrahepatic Cholangiocarcinoma2 trials
Gastric Adenocarcinoma1 trial
FGFR2 Fusions1 trial
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05174650·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Derazantinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company